B. Jagielska, A. Czubek, K. Tałasiewicz, Adam Twarowski, P. Rutkowski, M. Krzakowski, Bianka Saetre, M. Małecki
{"title":"基于总生存期（OS）和无病生存期（PFS）的统计分析确定曲妥珠单抗（赫赛汀）包括HER2+乳腺癌症患者辅助治疗的疗效评估","authors":"B. Jagielska, A. Czubek, K. Tałasiewicz, Adam Twarowski, P. Rutkowski, M. Krzakowski, Bianka Saetre, M. Małecki","doi":"10.26781/2052-8426-2018-02","DOIUrl":null,"url":null,"abstract":"\n \nAbstract: In patients suffering from breast cancer, adjuvant radiation, chemotherapy, or immunotherapy, which immediately follow the surgery as the first line therapy, greatly improve overall (OS) and disease-free survival (DFS). Various regimens of adjuvant therapy for these patients have been tested contingent upon the clinical staging. Inclusion of adjuvant immunotherapy is particularly promising. \n \n \n ","PeriodicalId":90271,"journal":{"name":"Molecular and cellular therapies","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2018-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Assessment of efficacy of trastuzumab (Herceptin) comprising adjuvant therapy of HER2+ breast cancer patients determined based upon statistical analysis of overall survival (OS) and disease-free survival (PFS)\",\"authors\":\"B. Jagielska, A. Czubek, K. Tałasiewicz, Adam Twarowski, P. Rutkowski, M. Krzakowski, Bianka Saetre, M. Małecki\",\"doi\":\"10.26781/2052-8426-2018-02\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n \\nAbstract: In patients suffering from breast cancer, adjuvant radiation, chemotherapy, or immunotherapy, which immediately follow the surgery as the first line therapy, greatly improve overall (OS) and disease-free survival (DFS). Various regimens of adjuvant therapy for these patients have been tested contingent upon the clinical staging. Inclusion of adjuvant immunotherapy is particularly promising. \\n \\n \\n \",\"PeriodicalId\":90271,\"journal\":{\"name\":\"Molecular and cellular therapies\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Molecular and cellular therapies\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.26781/2052-8426-2018-02\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular and cellular therapies","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26781/2052-8426-2018-02","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Assessment of efficacy of trastuzumab (Herceptin) comprising adjuvant therapy of HER2+ breast cancer patients determined based upon statistical analysis of overall survival (OS) and disease-free survival (PFS)
Abstract: In patients suffering from breast cancer, adjuvant radiation, chemotherapy, or immunotherapy, which immediately follow the surgery as the first line therapy, greatly improve overall (OS) and disease-free survival (DFS). Various regimens of adjuvant therapy for these patients have been tested contingent upon the clinical staging. Inclusion of adjuvant immunotherapy is particularly promising.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
